Because of the controversial nature of James Wright's review of cyclooxygenase NSAIDs,1 one might have expected CMAJ to go to great lengths to ensure adequate disclosure of competing interests. Although Wright listed his affiliation with the University of British Columbia Department of Pharmacology and Therapeutics, he did not mention his involvement with the Therapeutics Initiative, which is supported by BC Pharmacare. This represents a significant conflict of interest that should have been disclosed. The concomitant presentation of a contrary viewpoint would also have been welcome.
Walter P. Maksymowych Associate Professor and Consultant Rheumatologist University of Alberta Edmonton, Alta.
Reference
- 1.Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ 2002;167(10):1131-7. [PMC free article] [PubMed]